Clinical trials: Basal Ganglia Diseases
Parkinson Disease
Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease
To investigate the efficacy and the safety of ropinirole PR/XR tablets to ropinirole immediate release (IR) tablets with advanced Parkinson's disease in conjunction with L-dopa in a double-blind, parallel group comparison study.
- Trial name
- NCT00823836
- Testing
- ropinirole PR/XR, ropinirole IR
- Where
- 54 sites in Japan
- Volunteers
- 302 people
- Sponsor
- GlaxoSmithKline
Parkinson Disease
Robotic Walking Device to Improve Mobility in Parkinson's Disease
This Phase II randomized controlled trial proposes to examine the impact of long-term use of a novel light-weight and wearable assistive robotic device, called the Honda Walking Assist (HWA) device, to improve mobility in the…
- Trial name
- NCT03751371
- Testing
- Training with HWA device, Usual Care
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ohio State University
Idiopathic Parkinson's Disease
Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
This study is a 12-month, dose-level blinded, multicenter study of 2 inhaled dose levels of CVT-301 for the treatment of up to 5 OFF episodes per day in PD patients experiencing motor fluctuations (OFF episodes).
- Trial name
- NCT02242487
- Testing
- CVT-301
- Where
- 74 sites in United States, Canada and 3 more
- Volunteers
- 325 people
- Sponsor
- Acorda Therapeutics
Huntington's Disease
Coenzyme Q10 in Huntington's Disease (HD)
The goals of this trial are to determine if coenzyme Q10 is effective in slowing the worsening symptoms of Huntington's disease and to learn about the safety and acceptability of long-term coenzyme Q10 use by determining its…
- Trial name
- 2CARE (NCT00608881)
- Testing
- coenzyme Q10
- Where
- 49 sites in United States, Australia and 1 more
- Volunteers
- 609 people
- Sponsor
- Massachusetts General Hospital
Parkinson Disease
Continuous Wearable Monitor for the Detection and Release of Freezing of Gait.
The proposed system (haptic module and insole device) for daily in-community use that detects the occurrence of freezing of gait (FOG) in people with Parkinson's disease (PD).
- Trial name
- NCT06385392
- Testing
- Haptic module and insole device
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- HealthPartners Institute
Parkinson Disease
Efficacy Study of Light Therapy as an Adjunctive Treatment for Parkinson's Disease
Light treatment was originally employed in Parkinson's disease (PD) to determine if it might be effective in treating co-existing symptoms of depression and insomnia.
- Trial name
- NCT02175472
- Testing
- Spectramax light therapy device, Control light device
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 92 people
- Sponsor
- PhotoPharmics, Inc.
Wilson's Disease
A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease
The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult…
- Trial name
- GATEWAY (NCT04537377)
- Testing
- VTX-801
- Where
- 10 sites in United States, Denmark and 2 more
- Volunteers
- 4 people
- Sponsor
- Vivet Therapeutics SAS
Parkinson's Disease, Dyskinesia
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
The purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.
- Trial name
- NCT00105521
- Testing
- Sarizotan
- Where
- 32 sites in United States
- Volunteers
- 398 people
- Sponsor
- EMD Serono
Parkinson Disease, Multiple System Atrophy
Augmenting Effects of L-DOPS With Carbidopa and Entacapone
An experimental drug called L-DOPS increases production in the body of a messenger chemical called norepinephrine. Cells in the brain that make norepinephrine are often gone in Parkinson disease.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Autonomic Nervous System Diseases
- Trial name
- NCT00547911
- Testing
- Droxidopa, Carbidopa, Entacapone
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson's Disease
Telephone-linked Home-based Exercise Training in PD
This project is investigating whether a home-based exercise program will reduce depression in patients with Parkinson's disease.
- Trial name
- NCT02898740
- Testing
- Structural exercise, Health education
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- VA Office of Research and Development
Parkinson's Disease (PD)
Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
The purpose of this study is to investigate CYP2C9 inhibition by BIA 9-1067 through the assessment of its effect on the pharmacokinetics of S-warfarin, a substrate of CYP2C9.
- Trial name
- NCT02169440
- Testing
- BIA 9-1067, Warfarin
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Cognitive Rehabilitation for PD
To investigate the effectiveness of a novel compensatory cognitive rehabilitation program for individuals with Parkinson's disease (PD) and mild cognitive impairment (MCI).
- Trial name
- CogSMART-PD (NCT03335150)
- Testing
- CogSMART-PD, Supportive Care
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- VA Office of Research and Development
Parkinson Disease
Optimizing Protein Patterns for Skeletal Muscle Preservation and Sleep in the Medical Management of Parkinson Disease
The purpose of this pilot study is to generate preliminary data on the impact of the dietary protein pattern on markers of skeletal muscle health and drug efficacy in Parkinson disease.
- Trial name
- NCT05437640
- Testing
- Protein Redistribution Diet, Protein Consistent Diet
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Alabama at Birmingham
Parkinson Disease
Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic
To investigate the effect of repeated dosing of BIA 9-1067 on the levodopa pharmacokinetics, in comparison to placebo and entacapone.
- Trial name
- NCT01519284
- Testing
- BIA 9-1067 5 mg, Entacapone, levodopa/carbidopa
- Where
- Portugal
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine
This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of switching from ropinirole therapy to the rotigotine transdermal system and its effect on symptoms in subjects with idiopathic Parkinson's…
- Trial name
- NCT00593606
- Testing
- Rotigotine
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Amyotrophic Lateral Sclerosis, Parkinson Disease
Physiological Flow of Liquids Used in Dysphagia Management (Neuro)
For individuals with neurodegenerative conditions, such as Amyotrophic Lateral Sclerosis and Parkinson disease, swallowing impairment (i.e., dysphagia) is a common and serious symptom.
- Conditions
- Amyotrophic Lateral Sclerosis, Parkinson Disease, Dysphagia
- Trial name
- NCT03192358
- Testing
- Videofluoroscopic Swallowing Examination, Tongue Strength Measurement
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Parkinson Disease
Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients
To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of…
- Trial name
- NCT00144300
- Testing
- Mirapex, Requip
- Where
- 21 sites in United States
- Volunteers
- 246 people
- Sponsor
- Boehringer Ingelheim
Dementia With Lewy Bodies (DLB)
Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, proof-of-principle study of neflamapimod versus matching placebo (randomized 1:1) administered with food for 16 weeks in subjects with DLB.
- Trial name
- AscenD-LB (NCT04001517)
- Testing
- Neflamapimod
- Where
- 24 sites in United States, Netherlands
- Volunteers
- 91 people
- Sponsor
- EIP Pharma Inc
Parkinson's Disease
Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine
The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease.
- Trial name
- RECOVER (NCT00474058)
- Testing
- Rotigotine
- Where
- 47 sites in United States, Australia and 10 more
- Volunteers
- 287 people
- Sponsor
- UCB Pharma
Parkinson's Disease
Transcranial Direct Current Stimulation for Freezing of Gait
This study will evaluate the effects of transcranial direct current stimulation (tDCS) in combination with locomotor training in patients with Parkinson's disease (PD) and freezing of gait (FOG).
- Trial name
- TDCS-FOG (NCT02266004)
- Testing
- Transcranial Direct Current Stimulation (tDCS), locomotor training
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Miami